Sibanye Stillwater Ltd (SBSW) Stock Price Today
Aura AI Summary
Key Stats
- $6.47BMarket Cap
- 5,125,270Volume
- Basic MaterialsSector
- $21.1252W High
- $8.0052W Low
- 52 DaysTypical Hold Time
- $7.37BEnterprise Value
- 8.79%Div Yield
- -Trading Activity
Track Sibanye Stillwater Ltd (SBSW) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Sibanye Stillwater Ltd has traded between a low of $8 and a high of $21.12, highlighting its annual price range. Buy and sell Sibanye Stillwater Ltd shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Most Recent News
Norsk Hydro invites investors to its London investor day on Nov 25, with CEO and CFO presentations.
Norsk Hydro has announced an investor day event scheduled for November 25, 2026, in London at 30 Euston Square. The event will feature presentations and Q&A sessions with the CEO and CFO, followed by lunch and roundtable discussions exclusively for s...

Norsk Hydro invites investors to its London Investor Day on Nov 25, 2026, with virtual attendance option.
Norsk Hydro has announced its Investor Day event scheduled for November 25, 2026, in London, with an option to join virtually. The event will feature presentations and Q&A sessions with the CEO and CFO, followed by a roundtable exclusively for sell-s...

Microbiotica's MB097 shows safety and promising efficacy in advanced melanoma Phase 1b trial with KEYTRUDA.
Microbiotica presented positive Phase 1b trial results for MB097, a precision microbiome therapy combined with KEYTRUDA, in advanced melanoma patients resistant to anti-PD-1 therapy. The trial showed MB097 was safe, well tolerated, and led to signifi...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.